This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction (DILATE)

This study has been terminated.
(Recruitment was only stopped after the statistical power of the study was reached and the study objectives could be met despite the premature discontinuation.)
Information provided by (Responsible Party):
Bayer Identifier:
First received: July 19, 2010
Last updated: November 3, 2014
Last verified: November 2014
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction

Condition Intervention Phase
Hypertension, Pulmonary Ventricular Dysfunction, Left Drug: Riociguat (BAY63-2521) Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Pulmonary artery mean pressure at rest [ Time Frame: Peak change from baseline within 6 hours after a single dose of study drug ]

Secondary Outcome Measures:
  • Adverse event collection [ Time Frame: until 30 days after study drug treatment ]
  • Plasma concentrations to obtain pharmacokinetic profile of Riociguat [ Time Frame: Within 24 hours after study drug treatment ]

Enrollment: 39
Study Start Date: July 2010
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Riociguat (BAY63-2521)
0.5 mg single oral dose
Experimental: Arm 2 Drug: Riociguat (BAY63-2521)
1 mg single oral dose
Experimental: Arm 3 Drug: Riociguat (BAY63-2521)
2 mg single oral dose
Placebo Comparator: Arm 4 Drug: Placebo
single oral dose


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction

Exclusion Criteria:

  • Types of pulmonary hypertension other than group 2.2 of Dana Point Classification
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01172756

Linz, Oberösterreich, Austria, 4010
Graz, Steiermark, Austria, 8020
Graz, Steiermark, Austria, 8036
Salzburg, Austria, 5020
Wien, Austria, 1090
Czech Republic
Praha 2, Czech Republic, 12808
Köln, Nordrhein-Westfalen, Germany, 50924
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bayer Identifier: NCT01172756     History of Changes
Other Study ID Numbers: 14554
2010-018436-41 ( EudraCT Number )
Study First Received: July 19, 2010
Last Updated: November 3, 2014

Keywords provided by Bayer:
Pulmonary Hypertension
Left ventricular dysfunction

Additional relevant MeSH terms:
Hypertension, Pulmonary
Ventricular Dysfunction
Ventricular Dysfunction, Left
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Heart Diseases processed this record on September 21, 2017